Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending T
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
renal cell carcinoma
Biotech
Allogene links solid tumor CAR-T to responses, deaths in phase 1
Allogene linked the off-the-shelf cell therapy to a 33% response rate but also three deaths in heavily pretreated kidney cancer patients.
Nick Paul Taylor
Nov 8, 2024 4:47am
Arcus drops promising data on HIF-2a candidate in kidney cancer
Oct 24, 2024 2:48pm
Instil Bio takes the ax to its lead asset, cuts 60% of its staff
Dec 8, 2022 10:24am
FDA sinks Allarity’s plans for lead oncology asset
Aug 2, 2022 2:41pm
Despite 0% response rate, 4D hits primary goal in cancer trial
Mar 23, 2022 7:45am
FDA allows Allogene to resume CAR-T trials after safety scare
Jan 10, 2022 10:16am
